Erratum: Synthesis, Characterization and In Vitro Study of Biocompatible Cinnamaldehyde Functionalized Magnetite Nanoparticles (CPGF Nps) For Hyperthermia and Drug Delivery Applications in Breast Cancer (PLoS ONE (2014) 9:9 (e107315) DOI: 10.1371/journal.pone.0107315);Synthesis, characterization and in vitro study of biocompatible cinnamaldehyde functionalized magnetite nanoparticles (CPGF Nps) for hyperthermia and drug delivery applications in breast cancer

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Wani, Kirtee D ^a   Kadu, Brijesh S ^b   Mansara, Prakash ^a   Gupta, Preeti ^c   Deore, Avinash V ^d   Chikate, Rajeev C ^b   Poddar, Pankaj ^c   Dhole, Sanjay D ^d   Kaul Ghanekar, Ruchika ^a  

^a Bharati Vidyapeeth   (India)

^b ABASAHEB GARWARE COLLEGE   (India)

^c NATIONAL CHEMICAL LABORATORY   (India)

^d UNIVERSITY OF PUNE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CINNAMALDEHYDE; FERROUS SULFATE; GELATINASE A; GLYCINE; MAGNETITE NANOPARTICLE; POLOXAMER; POLYMER; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; VASCULOTROPIN; ACROLEIN; ANTINEOPLASTIC AGENT; BIOMATERIAL; DRUG CARRIER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL VIABILITY; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; ENZYME ACTIVATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HYPERTHERMIA; IN VITRO STUDY; MCF 7 CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; PARTICLE SIZE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SUSPENSION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; DRUG STABILITY; FEMALE; HYPERTHERMIC THERAPY; IC50; KINETICS;

ACROLEIN; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; FEMALE; GLYCINE; HEK293 CELLS; HUMANS; HYPERTHERMIA, INDUCED; INHIBITORY CONCENTRATION 50; KINETICS; MAGNETITE NANOPARTICLES; MCF-7 CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; POLOXAMER;

EID: 84907529733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0280492     Document Type: Erratum

References (50)

1. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD (2011) Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer. Breast Cancer Res 13: 1-9.
2. Schott AF, Hayes DF (2012) Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol 30: 1747-1749.
3. Binkley JM, Harris SR, Levangie PK, Pearl M, Guglielmino J, et al. (2012) Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. Cancer 118: 2207-2216.
4. Veronesi U, Marubini E, Del Vecchio M, Manzari A, Andreola S, et al. (1995) Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 87: 19-27.
5. Liao GS, Apaya MK, Shyur LF (2013) Herbal medicine and acupuncture for breast cancer palliative care and adjuvant therapy. Evid Based Complement Alternat Med 2013: 1-17.
6. Yin SY, Wei WC, Jian FY, Yang NS (2013) Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med 2013: 1-15.
7. Ahmed M, Khan MI, Khan MR, Muhammad N, Khan AU, et al. (2013) Role of medicinal plants in oxidative stress and cancer. Open Access Scientific Reports 2: 641.
8. Bhattaram VA, Graefe U, Kohlert C, Veit M, Derendorf H (2002) Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 9: 1-33.
9. Kareparamban JA, Nikam PH, Jadhav AP, Kadam VJ (2012) Phytosome: a novel revolution in herbal drugs. IJRPC 2: 299-310.
10. Bhadoriya SS, Mangal A, Madoriya N, Dixit P (2011) Bioavailability and bioactivity enhancement of herbal drugs by ''Nanotechnology'': a review. JCPR 8: 1-7.
11. Koppikar SJ, Choudhari AS, Suryavanshi SA, Kumari S, Kaul-Ghanekar R, et al. (2010) Aqueous cinnamon extract (ACE-c) from the bark of Cinnamomum cassia causes apoptosis in human cervical cancer cell line (SiHa) through loss of mitochondrial membrane potential. BMC Cancer 10: 210.
12. Singh R, Koppikar SJ, Paul P, Gilda S, Kaul-Ghanekar R, et al. (2009) Comparative analysis of cytotoxic effect of aqueous cinnamon extract from Cinnamomum zeylanicum bark with commercial cinnamaldehyde on various cell lines. Pharmaceutical Biology 47: 1174-1179.
13. Kwon BM, Lee SH, Choi SU, Park SH, Lee CO, et al. (1998) Synthesis and in vitro cytotoxicity of cinnamaldehydes to human solid tumor cells. Arch Pharm Res 21: 147-152.
14. Stammati A, Bonsi P, Zucco F, Moezelaar R, Alakomi HL, et al. (1999) Toxicity of selected plant volatiles in microbial and mammalian short-term assays. Food Chem Toxicol 37: 813-823.
15. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V (2005) Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm 2: 194-205.
16. Ren Y, Zhang H, Chen B, Cheng J, Cai X, et al. (2012) Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Int J Nanomedicine 7: 2261-2269.
17. Aljarrah K, Mhaidat NM, Al-Akhras MH, Aldaher AN, Albiss BA, et al. (2012) Magnetic nanoparticles sensitize MCF-7 breast cancer cells to doxorubicininduced apoptosis. World journal of surgical oncology 10:62.
18. Sadeghi-Aliabadi H, Mozaffari M, Behdadfar B, Raesizadeh M, Zarkesh- Esfahani H (2013) Preparation and cytotoxic evaluation of magnetite (Fe3O4) nanoparticles on breast cancer cells and its combinatory effects with doxorubicin used in hyperthermia. Avicenna J Med Biotech 5: 96-103.
19. Kikumori T, Kobayashi T, Sawaki M, Imai T (2009) Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast Cancer Res Treat 113: 435-41.
20. Berry CC, Curtis SG (2003) Functionalisation of magnetic nanoparticles for applications in biomedicine. J Phys D: Appl Phys 36: R198-206.
21. Hasany SF, Ahmed I, Rajan J, Rehman A (2012) Systematic review of the preparation techniques of iron oxide magnetic nanoparticles. Nanoscience and Nanotechnology 2: 148-158.
22. Petri-Fink A, Steitz B, Finka A, Salaklang J, Hofmann H (2008) Effect of cell media on polymer coated superparamagnetic iron oxide nanoparticles (SPIONs): colloidal stability, cytotoxicity, and cellular uptake studies. Eur - J Pharm Biopharm 68: 129-137.
23. Akbarzadeh A, Zarghami N, Mikaeili H, Asgari D, Goganian AM, et al. (2012) Synthesis, characterization, and in vitro evaluation of novel polymer-coated magnetic nanoparticles for controlled delivery of doxorubicin. Nanotechnology, Science and Applications 5: 13-25.
24. Williams CH, Lawson J, Colette FR (1988) Oxidation of 3-amino-1-phenylprop- 1-enes by monoamine oxidase and their use in a continuous assay of the enzyme. Biochem J 256: 911-915.
25. Shieh DB, Su CH, Chang FY, Wu YN, Su WC, et al. (2006) Aqueous nickelnitrilotriacetate modified Fe3O4-NH3 + nanoparticles for protein purification and cell targeting. Nanotechnology 17: 4174-4182.
26. Wani KD, Kitture R, Ahmed A, Choudhari AS, Kaul-Ghanekar R, et al. (2011) Synthesis, characterization and in vitro study of Curcumin-functionalized Citric acid-Capped Magnetic (CCF) Nanoparticles as drug delivery agents in cancer. Journal of Bionanoscience 5: 59-65.
27. Choudhari AS, Suryavanshi SA, Kaul-Ghanekar R (2013) The aqueous extract of Ficus religiosa induces cell cycle arrest in human cervical cancer cell lines SiHa (HPV-16 Positive) and apoptosis in HeLa (HPV-18 Positive). PLoS ONE 8: e7012.
28. Gonzales M, Krishnan KM (2007) Phase transfer of highly monodisperse iron oxide nanocrystals with Pluronic F127 for biomedical applications. Journal of Magnetism and Magnetic Materials 311: 59-62.
29. Ganta S, Devalapally H, Shahiwala A, Amiji M (2008) A review of stimuliresponsive nanocarriers for drug and gene delivery. Journal of Controlled Release 126: 187-204.
30. Poddar P, Telem-Shafir T, Fried T, Markovich G (2002) Dipolar interactions in two- and three-dimensional magnetic nanoparticle arrays. Phys Rev B66: 060403.
31. Shafi K, Ulman A, Dyal A, Yan X, Yang N, et al. (2002) Magnetic enhancement of c-Fe2O3 nanoparticles by sonochemical coating. Chem Mater 14: 1778-1787.
32. Paone JF, Abeloff MD, Ettinger DS, Arnold EA, Baker PR (1981) The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast. Surg Gynecol Obstet 152: 70-74.
33. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, et al. (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115: 423-428.
34. Rose DP, Vona-Davis L (2009) Influence of obesity on breast cancer receptor status and prognosis. Expert Review of Anticancer Therapy 9: 1091-1101.
35. Mauri FA, Maisonneuve P, Caffo O, Veronese S, Aldovini D, et al. (1999) Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: an immunohistochemical study on breast carcinoma with long-term follow-up. Int J Oncol 15: 1137-1147.
36. Bentzon N, During M, Rasmussen BB, Mouridsen H, Kroman N (2008) Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 122: 1089-94.
37. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS (1983) Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med 309: 1343-1347.
38. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. (2007) Triplenegative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434.
39. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, et al. (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative earlystage breast cancer. J Clin Oncol 24: 5652-5657.
40. Ismail IA, Kang HS, Lee HJ, Kwon BM, Hong SH (2012) 2'-Benzoyloxycinnamaldehyde- mediated DJ-1 upregulation protects MCF-7 cells from mitochondrial damage. Biol Pharm Bull 35: 895-902.
41. Aggarwal BB, Van Kuiken ME, Iyer LH, Harikumar KB, Sung B (2009) Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. Exp Biol Med (Maywood) 234:825-849.
42. Overall CM, López-Otín C (2002) Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer 2:657-672.
43. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, et al. (2004) Vascular Endothelial Growth Factor and Angiogenesis. Pharmacol Rev 56:549-580.
44. Quaranta M, Daniele A, Coviello M, Venneri MT, Abbate I, et al. (2007) MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res 27: 3593-3600.
45. Unemori EN, Ferrara N, Bauer EA, Amiento EP (1992) Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 153: 557-562.
46. Hilger I, Kaiser WA (2012) Iron oxide-based nanostructures for MRI and magnetic hyperthermia. Nanomedicine (Lond) 7: 1443-1459.
47. Kale SN, Jadhav AD, Verma S, Koppikar SJ, Kaul-Ghanekar R, et al. (2012) Characterization of biocompatible NiCo2O4 nanoparticles for applications in hyperthermia and drug delivery. Nanomedicine 8: 452-459.
48. Kong G, Braun RD, Dewhirst MW (2000) Hyperthermia enables tumor-specific nanoparticle delivery: Effect of particle size. Cancer Res 60: 4440-4445.
49. Asin L, Ibarra MR, Tres A, Goya GF (2012) Controlled cell death by magnetic hyperthermia: Effects of exposure time, field amplitude, and nanoparticle concentration. Pharmaceutical Research 29:1319-1327.
50. Song CW (1984) Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res 44: 4721-4730.